Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement

Combination of Elektrofi’s ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation